USE IR-Spectroscopy in treatment oncology patient with bone metastases by 153 Smoxabifor

Loading...
Thumbnail Image

Date

Editor(s)

Journal Title

Journal ISSN

Volume Title

Publisher

Национальный научный центр Харьковский физико-технический институт

Abstract

Using infrared spectroscopy, we studied the character of intermolecular interactions in the samples blood plasma of oncological patients with bone metastases in the treatment of their modern β-emitter 153Sm-oxabifor. The therapeutic dose of the 153Sm-oxabifor was 1.0 mCi/kg of the patient's body weight. Analysis of the IR-spectra showed that already after the rst course of palliative radionuclide therapy there is a tendency to balance the products of free radical nature and antioxidants, which indicates the e ectiveness of the treatment. Molecular changes in the blood plasma of cancer patients with bone metastases registered using infrared spectroscopy are speci c during palliative therapy.

Description

Citation

USE IR-Spectroscopy in treatment oncology patient with bone metastases by 153 Smoxabifor / N. P. Dikiy, N. V. Krasnoselsky, E. P. Bereznyak, A. V. Grushka, E. P. Medvedeva // Problems of atomic science and technology. – 2020. – N 5 (129). – Р. 46–51.

Endorsement

Review

Supplemented By

Referenced By